151 related articles for article (PubMed ID: 29042321)
1. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat.
Jucker BM; Alsaid H; Rambo M; Lenhard SC; Hoang B; Xie F; Groseclose MR; Castellino S; Damian V; Bowers G; Gupta M
J Control Release; 2017 Dec; 268():102-112. PubMed ID: 29042321
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
Jucker BM; Fuchs EJ; Lee S; Damian V; Galette P; Janiczek R; Macura KJ; Jacobs MA; Weld ED; Solaiyappan M; D'Amico R; Shaik JS; Bakshi K; Han K; Ford S; Margolis D; Spreen W; Gupta MK; Hendrix CW; Patel P
Br J Clin Pharmacol; 2022 Feb; 88(4):1655-1666. PubMed ID: 34240449
[TBL] [Abstract][Full Text] [Related]
3. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.
Spreen W; Ford SL; Chen S; Wilfret D; Margolis D; Gould E; Piscitelli S
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):481-6. PubMed ID: 25140909
[TBL] [Abstract][Full Text] [Related]
4. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
Spreen W; Williams P; Margolis D; Ford SL; Crauwels H; Lou Y; Gould E; Stevens M; Piscitelli S
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):487-92. PubMed ID: 25473882
[TBL] [Abstract][Full Text] [Related]
6. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
[TBL] [Abstract][Full Text] [Related]
7. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.
Yee KL; Mittal S; Fan L; Triantafyllou I; Dockendorf MF; Fackler PH; Stoch SA; Khalilieh SG; Iwamoto M
J Clin Pharm Ther; 2020 Oct; 45(5):1098-1105. PubMed ID: 32501541
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.
Port RE; Schuster C; Port CR; Bachert P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):607-17. PubMed ID: 16506037
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
12. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
[TBL] [Abstract][Full Text] [Related]
13. Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection.
Taha H; Morgan J; Das A; Das S
Recent Pat Antiinfect Drug Discov; 2013 Dec; 8(3):213-8. PubMed ID: 24738551
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.
van 't Klooster G; Hoeben E; Borghys H; Looszova A; Bouche MP; van Velsen F; Baert L
Antimicrob Agents Chemother; 2010 May; 54(5):2042-50. PubMed ID: 20160045
[TBL] [Abstract][Full Text] [Related]
15. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
[TBL] [Abstract][Full Text] [Related]
16. Matrix-assisted laser desorption ionization imaging mass spectrometry detection of a magnetic resonance imaging contrast agent in mouse liver.
Acquadro E; Cabella C; Ghiani S; Miragoli L; Bucci EM; Corpillo D
Anal Chem; 2009 Apr; 81(7):2779-84. PubMed ID: 19281170
[TBL] [Abstract][Full Text] [Related]
17. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
Gautam N; McMillan JM; Kumar D; Bade AN; Pan Q; Kulkarni TA; Li W; Sillman B; Smith NA; Shetty BLD; Szlachetka A; Edagwa BJ; Gendelman HE; Alnouti Y
Nat Commun; 2021 Jun; 12(1):3453. PubMed ID: 34103484
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous magnetic resonance imaging and pharmacokinetic analysis of intramuscular depots.
Probst M; Kühn JP; Scheuch E; Seidlitz A; Hadlich S; Evert K; Oswald S; Siegmund W; Weitschies W
J Control Release; 2016 Apr; 227():1-12. PubMed ID: 26899995
[TBL] [Abstract][Full Text] [Related]
19. Imaging of large volume subcutaneous deposition using MRI: exploratory clinical study results.
Pettis RJ; Woodley WD; Ossege KC; Blum A; Bolick NG; Rini CJ
Drug Deliv Transl Res; 2023 Sep; 13(9):2353-2366. PubMed ID: 36913105
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cefonicid in lactating goats after intravenous, intramuscular and subcutaneous administration, and after a long-acting formulation for subcutaneous administration.
Badillo E; Escudero E; Hernandis V; Galecio JS; Marín P
J Vet Pharmacol Ther; 2020 Jan; 43(1):50-56. PubMed ID: 31724779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
